Fenmetramide
Chemical compound
- None
- 2-Phenyl-3-methyl-morpholin-5-one
- 5588-29-4
- 21789
- 20479
- WCH9HW127L
- D04153
- DTXSID00863576
- Interactive image
- O=C1NC(C(OC1)c2ccccc2)C
Fenmetramide is a drug which was patented as an antidepressant by McNeil Laboratories in the 1960s.[1] The drug was never marketed.[2] It is the 5-ketone derivative of phenmetrazine and would similarly be expected to produce psychostimulant effects, though pharmacological data is lacking.
Synthesis
Ex 1: dl-Norephedrine Fb: [14838-15-4] (HCl): [154-41-6] was treated with NaH in mineral oil and later reacted with the ethyl chloroacetate [105-39-5]. Cis-product
Ex 2: dl-norpseudoephedrine was used => trans-product.
See also
- Fenbutrazate
- Phendimetrazine
- Phenmetrazine
- Flumetramide (Skeletal muscle relaxant)
References
- ^ a b US 3308121, Gannon WF, Poos GI, "3-Morpholinones, thiones and 5,6-oxazines", issued 7 March 1967, assigned to McNeil Laboratories
- ^ Triggle DJ (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 978-0-412-46630-4.
- ^ Clarke, Frank H. (1962). "cis- and trans-3-Methyl-2-phenylmorpholine". The Journal of Organic Chemistry 27 (9): 3251–3253. doi:10.1021/jo01056a063.
- ^ Spassov, S. L., Stefanovsky, J. N., Kurtev, B. J., Fodor, G. (August 1972). "Optisches Drehungsvermögen und Konformation, VI. Protonenresonanzspektren und Konformation einiger stereoisomerer 2.3‐disubstituierter Morpholine und 5‐Oxo‐morpholine". Chemische Berichte. 105 (8): 2467–2475. doi:10.1002/cber.19721050807.
- ^ W. Klyne, (the late), Scopes, P. M., Berova, N., Stefanovsky, J., Kurtev, B. J. (January 1979). "The circular dichroism of some derivatives of tetrahydro-1,3-oxazine, tetrahydro-1,4-oxazine(morpholine)and 1,3-oxazolidine". Tetrahedron. 35 (17): 2009–2012. doi:10.1016/S0040-4020(01)88970-5.
- v
- t
- e
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III